Peijia Medical Ltd. (HK:9996) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Peijia Medical Ltd. has announced the successful completion of the first compassionate use treatment with its TaurusTrio TAVR system in Hong Kong, targeting severe aortic regurgitation. The company recently finished patient enrollment for its clinical trial in China and is moving towards commercializing the system pending regulatory approval. This development could provide significant opportunities in the medical device market for investors.
For further insights into HK:9996 stock, check out TipRanks’ Stock Analysis page.